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Maple syrup urine disease (MSUD) is an inherited disorder of branched-chain amino acid metabolism presenting with life-
threatening cerebral oedema and dysmyelination in affected individuals. Treatment requires life-long dietary restriction and
monitoring of branched-chain amino acids to avoid brain injury. Despite careful management, children commonly suffer met-
abolic decompensation in the context of catabolic stress associated with non-specific illness. The mechanisms underlying this
decompensation and brain injury are poorly understood. Using recently developed mouse models of classic and intermediate
maple syrup urine disease, we assessed biochemical, behavioural and neuropathological changes that occurred during enceph-
alopathy in these mice. Here, we show that rapid brain leucine accumulation displaces other essential amino acids resulting
in neurotransmitter depletion and disruption of normal brain growth and development. A novel approach of administering
norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumula-
tion in milk as well as blood and brain of these pups to enhance survival. Similarly, norleucine substantially delayed encepha-
lopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown
to cause encephalopathy in human maple syrup urine disease. Current findings suggest two converging mechanisms of brain
injury in maple syrup urine disease including: (i) neurotransmitter deficiencies and growth restriction associated with branched-
chain amino acid accumulation and (ii) energy deprivation through Krebs cycle disruption associated with branched-chain
ketoacid accumulation. Both classic and intermediate models appear to be useful to study the mechanism of brain injury and
potential treatment strategies for maple syrup urine disease. Norleucine should be further tested as a potential treatment to
prevent encephalopathy in children with maple syrup urine disease during catabolic stress.
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Introduction
Branched-chain ketoacid dehydrogenase (EC 1.2.4.4) activity is
required for catabolism of branched-chain -ketoacids ketoiso-
caproate, ketomethylvalarate and ketoisovalarate, which are the
transamination products of branched-chain amino acids leucine,
isoleucine and valine, respectively. Autosomal recessive inheritance
of branched-chain ketoacid dehydrogenase deficiency, known as
maple syrup urine disease (MSUD), affects 1 : 100 000 children
worldwide (Mackenzie and Woolf, 1959; Chuang and Shih,
2001). However, MSUD affects children of old order Mennonite
families at a much higher frequency of 1 : 200 (Morton et al.,
2002). MSUD results in accumulation of branched-chain ketoacids
and branched-chain amino acids measured in blood, urine and
cerebrospinal fluid (Mackenzie and Woolf, 1959). If untreated,
affected individuals accumulate substantial branched-chain amino
acids, mostly leucine, and suffer encephalopathy within the first
week of life as well as cerebral oedema and dysmyelination with
chronic brain injury (Crome et al., 1961; Silberman et al., 1961;
Chuang and Shih, 2001). In some cases with an intermediate form
of MSUD, residual enzyme activity results in a delayed presenta-
tion (Chuang and Shih, 2001). The neuropathology associated
with MSUD involves vacuolation and oedema of the basal gan-
glia and brainstem as well as blunted dendritic development in
cortex (Crome et al., 1961; Silberman et al., 1961; Kamei et al.,
1992; Chuang and Shih, 2001).
Newborn screening for blood alloisoleucine levels45mm/l, pro-
duced from isoleucine accumulation, is considered diagnostic for
MSUD (Schadewaldt et al., 1999). Current therapy for MSUD
includes life-long maintenance of a low branched-chain amino
acid diet and regular monitoring of plasma branched-chain
amino acid levels (Morton et al., 2002). Emphasis is placed on
preventing leucinosis, but also avoiding leucine deficiency, which
can be equally life threatening. Aggressive treatment of inter-
current illness is used to prevent a catabolic state that can
rapidly lead to release of branched-chain amino acids from
muscle protein, leucinosis and cerebral oedema (Daniel et al.,
1977). Unfortunately, despite careful clinical management, some
children with MSUD become encephalopathic during intercurrent
illness and require intensive care hospitalization. Additionally, learn-
ing disabilities are found at a greater frequency in children and
adults with MSUD despite continuous management on special
diets (Morton et al., 2002; Schonberger et al., 2004; Simon
et al., 2007).
The recent development of mouse models for both classic and
intermediate MSUD provided the opportunity to study acute and
long-term consequences of metabolic decompensation associated
with branched-chain ketoacid dehydrogenase deficiency (Homanics
et al., 2006). The cMSUD mouse model was developed by tar-
geting the E2 subunit of the branched-chain ketoacid dehydro-
genase complex resulting in complete loss of enzyme activity
in homozygous offspring that die within three days of birth
(Homanics et al., 2006). The intermediate MSUD model was devel-
oped by transgenic addition of human E2 cDNA to heterozygous
classic MSUD mice under a liver specific promoter, resulting in
5–6% normal enzyme activity in liver of homozygous offspring
(Homanics et al., 2006). Approximately 80% of intermediate
MSUD mice survive until weaning, but then die by 8-weeks of
age (Homanics et al., 2006). Both models were shown to accu-
mulate branched-chain amino acids in blood and urine. However,
brain consequences have not been explored.
In the current study, we used intermediate MSUD mice to show
development of neuropathology with striking similarity to human
MSUD. Branched-chain amino acid accumulation in this model
was associated with neurotransmitter deficiency, behavioural
changes and limited survival. Providing intermediate MSUD mice
with a choice between normal and branched-chain amino acid-
free diet prevented brain injury and dramatically improved
survival. We then used classic MSUD mice to identify neuro-
pathological changes and follow the evolution of biochemical
derangement that occurred over the first few days of life simi-
lar to classic human MSUD. A novel treatment strategy using
norleucine was shown to delay encephalopathy and enhance
survival in both models. Our current findings indicate that both
the intermediate MSUD and classic MSUD models are useful
tools to study the mechanism of brain injury and to develop
potential interventions, which may prevent encephalopathy and
enhance long-term outcomes in children with MSUD.
Methods
Materials
All chemicals were purchased from Sigma (St Louis, MO, USA) unless
otherwise specified.
Animals
All mice were maintained at Penn State College of Medicine
(Department of Comparative Medicine) in accordance with IACUC
research guidelines set forth by Pennsylvania State University and
the Society for Neuroscience Policy on the use of animals in neuro-
science research. The intermediate MSUD mice, age-matched hete-
rozygous and wild-type (WT) controls, both of mixed genetic
background (Homanics et al., 2006), were generated from breeding
pairs in which both parents were heterozygous for knockout of the
endogenous mouse E2 gene and homozygous for both the LAP-tTA
and TRE-E2 transgenes (see Homanics et al., 2006 for additional
details of mouse production and genetic background). The classic
MSUD pups, WT and heterozygous controls were generated by
mating heterozygotes as previously described (Homanics et al.,
2006). Genotypes of all mice used in these studies were confirmed
by PCR of genomic DNA isolated from tail snips using the following
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primers: human E2 cDNA Left-GCAGGGTTTGATTGTCCCTA, Right-
TCAGCTGACCAGCTCACATT, mouse E2 gene Left-GCCAAGCTCAG
GTCCTTATG, Right-GCAGGCGTTGCTAGTGTTTT, PGKneo Left-GGA
GAGGCTATTCGGCTATG, Right-CTCGTCCTGCAGTTCATTCA.
Special diets
The diet without branched-chain amino acids was Dyets 510081
(Bethlehem, PA, USA). The normal diet was the Harland Teklad
2018 diet (Indianapolis, IN, USA), which is 18% protein. The high
protein diet was Harland Teklad TD.03637 (70% casein) and con-
tained 62% protein by weight. The high protein-norleucine diet was
prepared by adding 5% norleucine to the high protein diet. For low
branched-chain amino acid diet studies, male and female interme-
diate MSUD mice were placed on special diets at 3-weeks of age,
housed five per cage, observed every 12 h and the mice and diets
were weighed daily (n=30 for each study group). All special diet
treated animals and corresponding controls were evaluated daily
for symptoms as previously described (Zinnanti et al., 2006).
Behavioural evaluation
All animals and corresponding controls were evaluated for motor
deficits using a quantitative neurological scale developed previously
(Ouary et al., 2000; Zinnanti et al., 2006). Motor abnormalities
were scored on the presence and severity of motor symptoms consist-
ing of intermittent dystonia of one hindlimb, score = 1; intermittent
dystonia of two hindlimbs, score = 2; permanent dystonia of hindlimbs,
score = 3; gait abnormalities consisting mainly of uncoordinated, wob-
bling gait, score = 2; frequent falls or rolls, score = 2; recumbency,
score = 7; recumbency characterized by paralysis with rapid breathing,
score = 8; grasp reflex of forepaws, able = 0; unable = 1; and hindpaws
able = 0; unable = 1 was assessed. Motor abnormalities were assessed
daily and a neurological score was calculated for each animal as the
sum of all indices (minimum=0, normal animal; maximum=10, animal
showing near death recumbency).
Cage hang test was performed by placing the mouse on a wire
mesh cage lid and inverting the lid. The time that the mouse could
hang upside down without falling was recorded over three trials.
Histology
Mice were anesthetized with 100mg/kg pentobarbital (i.p.), perfused
with lactated Ringers (Baxter Deerfield, IL) followed by 4% parafor-
maldehyde for 15min. Brains were post-fixed in 4% paraformaldehyde
for 48 h, and paraffin embedded. Haematoxylin and eosin stained slides
were prepared from paraffin embedded brains. Sequential 10-mm thick
coronal brain slices were made within 0.5mm of the Bregma line for
striatal sections and between Bregma 5.5 and 6.25 for brain stem
sections (Franklin and Paxinos, 1997).
Immunohistochemistry and confocal
microscopy
Glial fibrillary acidic protein (GFAP) and neurofilament (N52) were
detected using deparaffinized 10-mm thick coronal brains slices.
Tissue was blocked with normal serum and incubated with poly-
clonal -GFAP (1 : 500) (Dako, Carpenteria, CA, USA) and monoclonal
-N52 (1 : 200) (Sigma) at the same time. All incubations were in
PBS with normal serum overnight at 4C. The slides were washed
separately three times each in PBS. Polyclonal GFAP was detected
with goat anti-rabbit coupled to Cy3 and N52 was detected with
goat anti-mouse coupled to Cy2 (all secondary antibodies diluted
1 : 2000; Jackson ImmunoResearch, West Grove, PA, USA). All slides
were counterstained with 40,60-Diamidino-2-phenylindole (DAPI)
0.1mg/ml in PBS for 5min. Confocal microscopy was performed using
a Leica TCS SP2 AOBS confocal microscope (Leica Microsystems
Wetzlar, Germany).
Biochemical analysis
All mice were sacrificed by focused beam microwave irradiation to
preserve brain metabolite status as previously described (O’Callaghan
and Sriram, 2004). Plasma, livers and brains were collected and frozen
to 80C. Samples were extracted with 8% perchloric acid (PCA) and
neutralized with potassium hydroxide as previously described (Williamson
and Corkey, 1979). All neutralized perchloric acid extracts were kept at
80C until analysis.
Amino acids
Plasma, brain and liver amino acids were derivatized with phenyl isothio-
cyanate (PITC) and separated and quantified by reverse-phase high-
performance liquid chromatography as previously described (Hariharan
et al., 1993) using a C18 ‘Econosphere’ column (1504.6mm ID, 3mm)
from Alltech (Deerfield, IL) with norvaline (100M) as an internal
standard.
Branched-chain ketoacids, pyruvate and -ketoglutarate were mea-
sured by HPLC as previously described (Loi et al., 2005). Brain extracts
were acidified and derivitized using O-phenylenediamine, separated by
HPLC using a CB18B ‘Econosphere’ column (1504.6mm ID, 3m)
from Alltech (Deerfield, IL, USA) and detected with fluorescence by
excitation and 350nm and absorbance at 410 nm.
ATP, lactate and phosphocreatine
Brain extracts were assayed for ATP, phosphocreatine and lactate
enzymatically (Williamson and Corkey, 1979). ATP was measured by
following the formation of NADPH spectrophotometrically using
hexokinase coupled with glucose-6-phosphate dehydrogenase in the
presence of glucose and NADP+. Phosphocreatine was measured by
adding creatine kinase to the above reaction and following the addi-
tional formation of NADPH. Lactate was measured by following the
formation of NADH using lactate dehydrogenase in the presence of
NAD+. Protein concentrations were measured by the method of Lowry
(Lowry et al., 1951).
MRI
MRI was performed on a 7.0 T Bruker system using a 2-mm birdcage
coil (n=6 mice per diet group). Mice were anesthetized with isoflurane
(1–1.5%) and imaged with a transverse relaxation time constant
(T2)-weighted multi-echo spin echo sequence (five 0.5-mm thick
slices, TR/TE=3000/10.6–148.4ms, 14 echoes, 117117mm resolu-
tion, two averages). T2 values were calculated on a pixel-by-pixel
basis from the corresponding exponential fits using CCHIPS software
(Schmithorst et al., 2001).
Statistics
Normally distributed data sets were analysed by ANOVA with Fisher
LSD post hoc test. Kruskal–Wallis one-way analysis of variance on
ranks was performed with Student–Neuman–Keuls post hoc test on
samples that were not normally distributed. Sigma Stat software
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(Jandel Scientific, San Rafael, CA, USA) was used for analysis. All
P50.05 were considered statistically significant.
Results
Behavioural changes and
neuropathology in intermediate
MSUD mice
Since most intermediate MSUD (iMSUD) mice were shown to
survive past weaning (Homanics et al., 2006), we first used this
model to identify behavioural changes and neuropathology.
Behavioural changes were evident in iMSUD mice at 3-weeks of
age including hypoactivity, hindlimb dystonia and uncoordinated
gait (Table 1). In surviving iMSUD mice, behavioural changes
became more severe over the next few weeks and included fre-
quent falls and intermittent recumbency. There were no behav-
ioural changes in heterozygous or WT littermate controls. To
identify neuropathological changes in iMSUD mice, we performed
MRIs beginning at 4-weeks of age. MRI of 4- and 6-week-old
iMSUD mice revealed moderate and severe neuropathological
changes in the striatum, thalamus and corpus callosum as indi-
cated by increased T2 signals (Fig. 1).
Histological sections of iMSUD mouse brains at 6-weeks of age
show pathologic changes localized to the striatum, thalamus and
brainstem (Fig. 2). Vacuolated white matter tracks were present in
the striatum and brainstem as well as diffuse vacuolation of grey
matter structures (Fig. 2B and D). Higher power confocal images
of similar sections reveal disruption of neuronal tracts in the stria-
tum with reactive astrocytes (Fig. 2F). Confocal images of the
brainstem of iMSUD mice reveal depleted neurons and neural net-
works with reactive astrocytosis (Fig. 2H). These changes are strik-
ingly similar to neuropathology reports for human MSUD (Crome
et al., 1961; Silberman et al., 1961) and show a similar pattern of
neuronal disruption likely indicating the brain regions most depen-
dent on normal branched-chain ketoacid dehydrogenase function.
Branched-chain amino acid
accumulation was associated with
growth restriction and reduced
survival in iMSUD mice
The iMSUD mice maintained on a normal diet survived a maxi-
mum of 8 weeks (Fig. 3A) with most of these mice dying between
5 and 8 weeks as previously reported (Homanics et al., 2006).
There was no reduced survival of WT or heterozygous littermates
of iMSUD mice (Fig. 3A). Body weights of iMSUD mice were 25
and 30% lower than age-matched heterozygous littermate con-
trols at 3- and 4-weeks of age, respectively (Fig. 3B). Examination
of individual organs (brain, kidney and liver) revealed a dispropor-
tionate growth restriction in the brain of 70% in 4-week-old
iMSUD mice compared with age-matched controls (Fig. 3B).
These changes were accompanied by substantial branched-chain
amino acid accumulation in blood, brain and liver (Fig. 3C) with
the greatest accumulation of leucine compared with valine and
isoleucine in plasma, similar to reports of leucinosis in human
MSUD (Morton et al., 2002). Alloisoleucine, considered diagnostic
for MSUD, was 460-fold increased in blood (126 48 versus
2 1mmol/l) and 45-fold increased in liver (375 92 versus
65 20 mmol/kg wet wt) of iMSUD mice compared with hetero-
zygous controls, respectively (Fig. 3C). Alloisoleucine was not
detected in brain tissue of iMSUD mice or controls.
Branched-chain amino acid accumulation in human MSUD is
associated with alterations of other amino acids (Wajner et al.,
2000; Morton et al., 2002), therefore we measured large neutral,
small neutral and basic amino acids in blood, brain and liver from
iMSUD mice. Similar to human MSUD, large neutral amino acids,
threonine and tyrosine, were significantly reduced in blood along
with small neutral amino acid, alanine (Fig. 3D) (Wajner et al.,
2000; Morton et al., 2002). However, unlike human data,
Table 1 Average neurologic scores in surviving iMSUD
mice on a normal diet
Neurologic
score
3–4 weeks of
age (n =16) (%)
5–6 weeks of
age (n =12) (%)
7–8 weeks of
age (n = 4) (%)
3–4 70 30 0
5–6 30 50 50
7–10 0 20 50
See behavioural evaluation in Methods section for neurologic score
determinations.
>80
0
70
40
30
20
10
50
60
C 
A 6wk Heterozygote
B 4wk iMSUD
6wk iMSUD
T2[ms]
Figure 1 Neuropathology in iMSUD mice detected by MRI.
(A) T2 maps (top) and T2 weighted brain images (bottom)
of a heterozygote control at 6wk of age (6 weeks) from left to
right, caudal to rostral. (B) Similar images from an iMSUD
mouse at 4-weeks of age show increased T2 signals in the
striatum (red arrows) and thalamus (green arrows).
(C) At 6-weeks of age an iMSUD mouse shows enlarged
ventricles (blue arrows), increased T2 signals in the striatum
(red arrows), thalamus (green arrows) and fluid collection along
the white matter tracts of the corpus callosum (white arrows).
[Colour bar indicates T2 values (right side)].
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tryptophan was significantly increased in blood of iMSUD mice
compared with controls (Fig. 3D) (Wajner et al., 2000). In brain,
threonine, tryptophan and tyrosine were all reduced while levels of
lysine and alanine were increased in iMSUD mice compared with
WT and heterozygous controls (Fig. 3D). These data are consistent
with previous studies using leucine loading in rats (Araujo et al.,
2001) and cerebral spinal fluid samples of MSUD patients (Wajner
et al., 2000). In contrast, threonine, tryptophan, tyrosine and
lysine were all increased in liver while alanine levels were reduced
in iMSUD mice (Fig. 3D). These data are consistent with brain
specific growth restriction and suggest that accumulating
branched-chain amino acids compete with essential large neutral
amino acida for brain access through the large neutral amino acid
transporter (LAT1) (Killian and Chikhale, 2001). Alternatively, the
increased amino acid levels in liver may indicate an enhanced
catabolic state (Daniel et al., 1977).
Depletion of essential large neutral amino acida in iMSUD
mouse brains may affect neurotransmitter levels, especially dopa-
mine, which is dependent on available tyrosine. Therefore, we
investigated the possibility of neurotransmitter deficiencies in
iMSUD mice (Fig. 3E). Depletion of neurotransmitters included
decreased glutamate and aspartate levels by 440%, GABA by
20% and dopamine by 460% (Fig. 3E). Reduced dopamine
levels are consistent with depleted precursor, tyrosine, in blood
and brain of iMSUD mice and blood of MSUD patients (Morton
et al., 2002). Depletion of glutamate, GABA and aspartate is con-
sistent with previous findings in newborn MSUD calves (Dodd
et al., 1992) and may indicate impaired glutamate cycling or dis-
rupted energy metabolism secondary to branched-chain ketoacid
accumulation as previously suggested (Patel et al., 1973, 1974;
Yudkoff et al., 2005).
Rapid postnatal branched-chain
amino acid accumulation limits
neuronal development and survival
of classic MSUD mice
The limited survival of classic MSUD (cMSUD) mice suggested that
similar pathological changes found in iMSUD mice might evolve
more rapidly in cMSUD mice. Therefore, we examined blood,
brain and liver from infant cMSUD mice over the first few days
of life for development of neuropathology that correlated with
metabolic decompensation (Figs 4 and 5). Comparison of confocal
images from motor cortex of cMSUD and heterozygous mice
shows disruption of neurofilaments and reactive astrocytosis in
cMSUD mice at 3 days of age (Fig. 4A and B). These changes
are consistent with reports of abnormal and decreased dendritic
development in human MSUD (Kamei et al., 1992). Survival of
cMSUD mice is limited to 3 days of life (Fig. 4C) as previously
reported and there were no significant differences in body or brain
weights between newborn cMSUD mice and littermate controls
(Homanics et al., 2006). All three branched-chain amino acids
were significantly higher in blood, brain and liver of newborn
cMSUD mice compared with heterozygous controls (Fig. 4D).
However, leucine levels rose exponentially in blood and brain of
cMSUD mice over postnatal day 1 and 2, while liver levels
increased linearly (Fig. 4D). Similar to human MSUD, alloisoleucine
Figure 2 Neuropathology in iMSUD mice by light and confocal microscopy. Coronal sections from a heterozygote control (A and C)
show the normal appearance of cortex and striatum (A) as well as cerebellum and brainstem (C). Similar sections from an iMSUD
mouse at 6-weeks of age show striatal vacuolation (B) and disruption of white matter patches in the striatum (inset B, white arrow).
Additionally, white matter structures in the brainstem were shown to be disrupted in iMSUD mice (D and inset, white arrow).
Confocal images of similar sections as in A–D show disruption of neuronal processes (green) in the striatum (F) and the brainstem
(H) with astrocytosis of iMSUD mouse compared with heterozygotes control (E and G, respectively). (AND: H&E, inset 25;
E–H: N52-green, GFAP-red and DAPI-blue).
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blood levels were indistinguishable from heterozygous controls
(2 1 mmol/l) until the third day of life (8 2 mmol/l) (Fig. 4D).
Accordingly, liver alloisoleucine levels were similar to control, but
more than doubled on the third day of life in cMSUD mice only
(342 48 mmol/kg wet wt) (Fig. 4D).
Comparable with iMSUD mice, leucine accumulation in cMSUD
mice was associated with changes in other large neutral, basic
and small neutral amino acids as well as neurotransmitter deple-
tion (Fig. 5). Comparing blood from newborn cMSUD mice and
heterozygous controls, threonine, tryptophan and alanine levels
were similar, but then decreased significantly over the first few
days of life (Fig. 5). Blood lysine levels were unchanged in
cMSUD mice compared with controls, but tyrosine levels were
reduced and remained lower than controls through postnatal
day 2 (Fig. 5). These changes are similar to those found in
human MSUD (Wajner et al., 2000) and further indicate differ-
ences exacerbated by leucine accumulation.
Brain threonine, tryptophan, lysine and alanine levels were similar
comparing newborn cMSUD with heterozygous controls, although
brain tyrosine levels were lower in cMSUD mice (Fig. 5). Both thre-
onine and tyrosine were progressively decreased in the brain of
cMSUD mice while these levels were shown to increase in hetero-
zygous mice over the same period (Fig. 5). Alanine levels increased
in cMSUD brains compared with controls over the first few days
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Figure 3 Limited survival, body and brain weights associated with biochemical derangement in iMSUD mice. (A) Survival of iMSUD
mice is limited compared with heterozygous controls both on a normal diet (ND) (n=20 per group). (B) Body weight of iMSUD mice
at 3- and 4-weeks of age compared with WT and heterozygous controls. Brain weight of iMSUD mice at 4-weeks of age was about
one-third of WT and heterozygous age-matched controls. (C) Plasma, brain and liver branched-chain amino acids of iMSUD compared
with WT and heterozygous controls. (D) Large neutral, basic and small neutral amino acid changes in plasma, brain and liver associated
with increased branched-chain amino acids in iMSUD mice. (E) Whole brain neurotransmitter changes associated with branched-chain
amino acids accumulation in iMSUD mice compared with WT and heterozygous controls all on a normal diet at 6-weeks of age.
(Mean SEM, P50.01, n=6 each group).
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of life. Glutamate, glutamine, aspartate, GABA and dopamine levels
were similar in newborn cMSUD mice and heterozygous controls,
but each declined by postnatal day 2 in cMSUD mice (Fig. 5). These
changes are similar to those found in 6-week-old iMSUD mice and
newborn MSUD calves (Dodd et al., 1992), although to a greater
magnitude in a shorter period of time for cMSUD mice. The devel-
opment of these changes during an exponential rise in plasma and
brain leucine levels suggests a causative relationship and provides
further evidence for competition at the blood–brain barrier between
leucine and other essential large neutral amino acids.
In newborn cMSUD liver, threonine, lysine and tyrosine levels
were similar to controls, but tryptophan and alanine were lower
(Fig. 5). Over the first few days of life, tryptophan levels increased
to match controls, lysine increased above control levels and ala-
nine and tyrosine levels were both reduced in cMSUD liver com-
pared with controls (Fig. 5). Increased brain and liver lysine levels
with decreased plasma alanine suggests increased ketone body
utilization and reduced gluconeogenesis as previously shown in
other models (Daniel et al., 1977; Zinnanti et al., 2007). These
changes likely represent events that contribute to biochemical
decompensation associated with brain injury in MSUD.
Low branched-chain amino acid diet
improves survival and prevents brain
injury in iMSUD mice
Standard treatment for maple syrup urine disease is life-long low
branched-chain amino acid diet (Chuang and Shih, 2001; Morton
et al., 2002). Survival of some iMSUD mice to weaning (3-weeks
of age) provided the opportunity to test the effect of a low
branched-chain amino acid diet for this MSUD mouse model. At
3-weeks of age iMSUD mice were provided equal access to both
normal and branched-chain amino acid-free diet. This method
takes advantage of the rodent’s ability to discriminate between
diets as previously reported (She et al., 2007). The iMSUD mice
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Figure 4 Neuropathology and limited survival associated with postnatal branched-chain amino acid accumulation in cMSUD mice.
Confocal images of motor cortex from a heterozygous control (A) and cMSUD mouse (B) both at 3 days of age (A and B: N52-green,
GFAP-red and DAPI-blue). (C) Survival of cMSUD mice is limited to postnatal day 2 or 3 compared with normal survival of
heterozygous controls both on a normal diet (ND) (cMSUD n=20, Hetero n=36). (D) Plasma, brain and liver branched-chain
amino acids were substantially increased in newborn (NB), 1- and 2-day-old cMSUD mice compared with heterozygous (Het)
controls (Note different scale for cMSUD and Hetero, and 5x scale for alloisoleucine plasma levels, Mean  SEM, P50.01,
n=6 each group).
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consumed an average of 3.6 g of diet daily (73% branched-chain
amino acid-free diet and 27% normal diet, n=20). Consumption
of this low branched-chain amino acid diet resulted in reduced
plasma and brain branched-chain amino acid accumulation,
increased survival and neuronal protection (Fig. 6). Eighty percent
of iMSUD mice survived for41 year on the low branched-chain
amino acid diet. We performed MRI on iMSUD mice and hetero-
zygous controls that were exposed to the low branched-chain
amino acid diet for 8-weeks (Fig. 6A and B). The iMSUD mice
maintained on the low branched-chain amino acid diet had
slightly increased T2 signals throughout the brain compared
with controls indicating increased water content. Similar changes
have been reported in non-encephalopathic adolescent and
adult patients with MSUD (Schonberger et al., 2004). There
was no evidence of behavioural changes such as those found
in iMSUD mice on a normal diet (Fig. 1). Furthermore, there
was no difference in brain weights compared with heterozygous
controls.
The low branched-chain amino acid diet reduced plasma leucine
levels to within 2-fold of control values and reduced brain leucine
to control levels in iMSUD mice (Fig. 6D). Plasma alloisoleucine
levels were reduced450% in iMSUD mice on the low branched-
chain amino acid diet, but remained about 20-fold higher than
control levels (44 15 mmol/l) (Fig. 6D). Other large neutral,
basic and small neutral amino acids were regulated to within
control values in plasma and brain, except for plasma alanine
that remained low and brain tyrosine that was further reduced
(Fig. 6E). These data demonstrate the protective effect of a low
branched-chain amino acid diet to reduce brain leucine accu-
mulation through dietary manipulation. Additionally, the reduced
brain branched-chain amino acid levels correlate with increased
availability of other essential large neutral amino acids and
normal brain development.
High protein challenge reveals energy
deprivation in MSUD encephalopathy
The response of iMSUD mice to a low branched-chain amino acid
diet provided the opportunity to challenge these mice with a high
protein diet, which may mimic the catabolic state considered to
cause the most severe episodes of biochemical intoxication in
patients with MSUD (Morton et al., 2002). Heterozygous con-
trols and iMSUD mice were maintained on a low branched-
chain amino acid diet for 3 weeks. Half of each group was
placed on the high protein diet and all were monitored for beha-
vioural and biochemical changes. Heterozygous mice exposed to
the high protein diet and iMSUD mice maintained on a low
branched-chain amino acid diet did not show any behavioural
changes (Fig. 7A and B). After 48 h of high protein diet exposure,
iMSUD mice developed widening of hind leg stance, unsteady gait
Figure 5 Plasma, brain and liver amino acid changes over the first few days of life in cMSUD mice. Plasma threonine, tryptophan,
lysine, alanine and tyrosine in newborn (NB), postnatal day 1 and day 2 of cMSUD compared with heterozygous control mice
(Mean SEM, P50.01, n=6 each group). Brain threonine, tryptophan, lysine, alanine, tyrosine, glutamate, glutamine, aspartate,
GABA and dopamine in NB, postnatal day 1 and 2 of cMSUD mice compared with heterozygous controls (Mean SEM, P50.01,
n=6 each group). Liver threonine, tryptophan, lysine, alanine and tyrosine levels in cMSUD and heterozygous control mice over
the first few days of life (Mean SEM, P50.01, n=6 each group).
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and left or right sided weakness with frequent rolls or falls to the
weak side (Fig. 7A and B). These changes were similar to those
observed in iMSUD mice on a normal diet between 3 and 6 weeks
of age (Table 1). Within 72 h of protein diet exposure, iMSUD
mice developed intermittent recumbency and extensor posturing,
which was exacerbated by stimulating the animal with mild tail
pressure (Fig. 7C and D). These behavioural changes are similar to
reports of severe dystonia in children with MSUD during acute
decompensation (Crome et al., 1961; Silberman et al., 1961;
Morton et al., 2002; Jan et al., 2003) and may represent an
animal model of opisthotonus.
Progressive biochemical decompensation accompanied behav-
ioural changes between 48 and 72 h in iMSUD mice exposed to
high protein. At 48 h, brain leucine levels increased more than
4-fold and -ketoisocaproate (KIC) increased more than 10-fold
compared with low branched-chain amino acid diet and hetero-
zygous controls (Fig. 7E). At 72 h, high protein exposure raised
cerebral leucine levels another 3-fold as KIC levels doubled.
Figure 6 Low branched-chain amino acid diet protects brain and increases survival of iMSUD mice. (A) T2 maps (top) and T2-weighted
brain images (bottom) of a heterozygous control at 8-weeks of age from left to right, caudal to rostral. (B) Similar images from
an iMSUD mouse at 8-weeks of age show only slight increase in T2 signals throughout the brain. [Colour bar indicates T2 values
(right side)] (C) Survival of iMSUD mice on a low branched-chain amino acid diet compared to normal diet (n=40 per group).
(D) Plasma and brain branched-chain amino acids in iMSUD mice and heterozygous controls allowed to select a low branched-chain
amino acid diet compared with iMSUD normal diet controls at 6-weeks of age. (E) Plasma and brain large neutral, basic and small
neutral amino acids in iMSUD mice and heterozygous controls allowed to select a low branched-chain amino acid diet compared
with iMSUD normal diet controls at 6-weeks of age (Mean SEM, P50.01 compared with iMSUD ND, †P50.01 compared
with hetero, n=6 each group).
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Plasma alloisoleucine levels did not change significantly with high
protein exposure (not shown). At 48 h, GABA levels were depleted
by 20% and dopamine levels were reduced by 50% in the brain
of iMSUD mice exposed to high protein (Fig. 7F). After 72 h, both
GABA and dopamine levels were reduced to one-third of control
levels. These changes are consistent with appearance of motor
impairment involving initiation and control and further correlate
with striatal damage found in these mice and children with
MSUD (Hauber, 1998; Morton et al., 2002). Additionally, gluta-
mate levels were reduced by 50% at 48 h and further reduced at
72 h of high protein exposure (Fig. 7G) while glutamine levels
remained unchanged during this period (not shown). Alanine
levels were increased by about 12% at 48 h and another 11%
at 72h in the brain of iMSUD mice on the high protein diet
(Fig. 7G).
Glutamate depletion with alanine accumulation may indicate
impaired energy metabolism (Regunathan and Sundaresan, 1984).
To evaluate the status of energy metabolism in the brain, we
measured -ketoglutarate (KG), pyruvate, lactate, ATP and
phosphocreatine levels. In iMSUD mice maintained on a low
branched-chain amino acid diet, pyruvate levels were 450%
reduced compared with heterozygous controls, although KG,
lactate, ATP and phosphocreatine levels were similar in both
groups (Fig. 7H). After 48h of high protein diet exposure, KG
was elevated by 25% and pyruvate was further decreased as
lactate more than doubled (Fig. 7H). However, ATP and
phosphocreatine levels were unchanged at 48h in iMSUD mice
on the high protein diet compared with controls (Fig. 7H). At
72h, KG increased 50% 448-h levels, pyruvate was further
depleted and lactate increased to more than 3-fold control levels
(Fig. 7H). At this time, ATP and phosphocreatine levels were sub-
stantially depleted compared with 48-h levels and controls. These
brain biochemical changes are consistent with the development of
severe behavioural deficits at 72h.
Norleucine prevents aKIC accumulation
and delays encephalopathy in iMSUD
mice
Atypical amino acid, norleucine, has been shown to effectively
compete with leucine at the blood–brain barrier for brain access
(Tews et al., 1991). Therefore, we tested the ability of norleucine
to reduce branched-chain amino acid accumulation and improve
survival in iMSUD mice on a high protein diet. Supplementing
the high protein diet with 5% norleucine resulted in survival of
80% of iMSUD mice for up to 5 days, 40% up to 7 days and
20% longer than 8 days compared with 2–3 day survival on the
high protein diet alone (Fig. 8A). Norleucine supplementation
delayed the onset of encephalopathy in iMSUD mice based on
average neurologic scores for each group (Fig. 8B). The cage
hang test was highly sensitive for treated versus untreated
Fig. 7 Behavioural and biochemical changes in iMSUD mice challenged with a high protein diet. (A–D) Comparison of behavioural
changes in heterozygous (blue arrow) and iMSUD mice 48h (green arrow) and 72h (red arrow) after high protein diet exposure.
At 48 h iMSUD mice showed unsteady gait with predominant left sided weakness (A, green arrow) resulting in frequent rolls (B, green
arrow). At 72 h iMSUD mice became intermittently recumbent (A–D, red arrow) and exhibited intermittent extensor posturing
(compare C and D). (E–H) Brain biochemical changes in iMSUD mice challenged with high protein compared with low branched-chain
amino acid diet and heterozygous controls. (Mean SEM, P50.01, P50.001 compared with iMSUD low BCAA diet and hetero,
†P50.01, compared with hetero only, n=6 each group).
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groups (Fig. 8B). These data indicate a protective effect of norleu-
cine to delay encephalopathy.
To evaluate the protective effect of norleucine, we examined
brain biochemical changes with and without treatment in high
protein challenged iMSUD mice for 2 days compared with low
branched-chain amino acid diet controls (Fig. 8C–E). Norleucine
treatment reduced brain leucine levels by420%, although there
was no difference in valine or isoleucine compared with untreated
controls (Fig. 8C). Glutamate, aspartate and GABA were all pro-
tected by norleucine treatment, although dopamine was still
depleted compared with untreated iMSUD mice challenged with
high protein (Fig. 8C). Of the large neutral amino acids, trypto-
phan was partially protected by norleucine treatment, but tyrosine
was not, consistent with depleted dopamine levels. Both lysine and
alanine were lower with norleucine treatment (Fig. 8D). Taken
together these data suggest that norleucine may be more
effective in protecting energy metabolism than in preventing
brain branched-chain amino acid accumulation. Consistent with
this hypothesis, KIC levels were substantially reduced with nor-
leucine treatment and pyruvate and KG were restored to near
normal levels compared with high protein diet alone (Fig. 8E).
Reduced levels of KIC and protected levels of glutamate, aspar-
tate and GABA suggest that norleucine may inhibit transamination
of leucine (formation of KIC) in the brain.
Norleucine treatment improves survival
of suckling cMSUD mice
The rapid decompensation of newborn cMSUD mice over the first
few days of life poses a significant challenge to testing potential
treatments. If a treatment can be effective in this model, it is more
Figure 8 Norleucine improved survival, behaviour and neurochemistry of iMSUD mice challenged with a high protein diet.
(A) Survival of adult iMSUD mice challenged with a high protein diet (Hi Pro), or challenged with a high protein diet containing
5% norleucine (Hi Pro 5% Norleu) (n=20 per group). (B) Average neurological score of iMSUD mice challenged with the high
protein diet compared with and without 5% norleucine (n=5 per group). Cage hang test compared the time (seconds) over three
trials for iMSUD mice to hang upside down after 48 h of high protein diet with and without 5% norleucine (n=5 per group).
(C) Branched-chain amino acid, glutamine and neurotransmitter levels. (D) Large neutral, basic and small neutral amino acid levels.
(E) KIC, pyruvate and KG levels in brain of iMSUD mice challenged with a high protein diet with and without 5% norleucine
compared with low branched-chain amino acid diet controls. (Mean SEM, P50.01, compared with iMSUD high protein without
treatment, n=6 each group).
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likely to be effective in human MSUD. Since these infant mice are
dependent on suckling, we hypothesized that treatment may be
possible through the heterozygous mothers. We first tested this
possibility by placing the pregnant mothers on a low branched-
chain amino acid diet one week before giving birth. Compared
with normal diet controls, this provided minimal improvement as
50% of cMSUD offspring survived one additional day (Fig. 9A).
Based on the effect of norleucine to compete with branched-
chain amino acid transport (Tews et al., 1991), we hypothesized
that norleucine supplementation of heterozygous mothers may
provide a low branched-chain amino acid milk and improve
survival of suckling cMSUD mice. Supplementation of pregnant
heterozygous mothers with 1% norleucine, added to daily water
intake, allowed 60% of infant cMSUD mice to survive up to
8 days compared with 2–3 day survival in untreated controls
(Fig. 9A). Both body and brain weight of cMSUD mice from
treated mothers were 30% reduced compared with heterozy-
gous controls with and without norleucine treatment (Fig. 9B).
These data indicate a substantial improvement in survival with
norleucine treatment. Although growth restriction is still present,
similar to iMSUD mice on a normal diet, disproportionate brain
growth restriction is eliminated suggesting better availability of
essential large neutral amino acids in the brain of cMSUD mice.
Since cMSUD mice normally survive only 2–3 days, we used
biochemical findings in 2-day-old untreated cMSUD mice to
compare with norleucine treated mice at postnatal day 7. Milk
taken from the stomach of infant cMSUD mice and heterozygous
littermates from either norleucine treated or untreated mothers
showed a 40% reduction in leucine content with treatment
(Fig. 9C). Plasma leucine levels were reduced by 70% in hetero-
zygous littermates but not cMSUD pups from norleucine treated
mothers compared with untreated controls (Fig. 9C). Although
there was no difference, the similar levels likely represent delayed
accumulation in the 5-day-older treated group. Accordingly, there
was no significant difference in plasma alloisoleucine levels with
norleucine treatment (not shown). Brain leucine levels were
Figure 9 Norleucine treatment improved survival and neurochemistry in infant cMSUD mice. (A) Survival of suckling cMSUD
mice from mothers on a normal diet (ND), low branched-chain amino acid diet or with 1% norleucine added to daily water intake
(n=20 per group). (B) Body and brain weight of cMSUD mice after 1 week of norleucine treatment through mothers compared
with heterozygous controls with and without norleucine treatment. (C) Leucine content of milk taken from the stomach of cMSUD
or heterozygous mice with and without norleucine treatment of the mothers. Plasma and brain leucine concentrations and brain
KIC in cMSUD and heterozygous control mice with and without norleucine treatment of mothers. (D) Large neutral, basic and
small neutral amino acid levels in brain of cMSUD and heterozygous mice with and without norleucine treatment. (E) Brain glutamine
and neurotransmitter levels in cMSUD and heterozygous mice with and without norleucine treatment. (Mean SEM, P50.01,
compared with cMSUD without treatment, n=6 each group).
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reduced by 30% in cMSUD pups and 20% in heterozygous pups
from treated mothers compared with untreated controls (Fig. 9C),
indicating the effectiveness of norleucine to control brain leucine
levels. Additionally, KIC was reduced by 60% in the brain of
cMSUD mice from treated mothers (Fig. 9C). These changes are
consistent with data from iMSUD mice and support the role of
norleucine to inhibit transamination of leucine to KIC in addition
to reducing brain leucine accumulation.
Norleucine was present in plasma and brain of cMSUD mice
and heterozygous controls from mothers treated with norleucine,
indicating that norleucine crosses into the milk, blood and brain
of the suckling mice (not shown). Tryptophan and tyrosine were
lower in the brain of cMSUD but not heterozygous pups from
norleucine treated mothers compared with untreated controls
(Fig. 9D). Brain lysine and alanine were both reduced in cMSUD
pups with norleucine treatment (Fig. 9D), which may reflect pro-
tection of energy metabolism in the brain similar to changes found
in iMSUD mice (Fig. 8). Glutamate, aspartate and GABA levels
were increased in cMSUD pups from treated mothers compared
with untreated controls (Fig. 9E). However, dopamine levels were
further reduced with norleucine treatment consistent with the
reduced brain tyrosine levels (Fig. 9E). The protective effect of
norleucine in preserving brain glutamate, aspartate and GABA
levels correlates with reduced KIC levels.
Discussion
In the current study, we correlate biochemical, behavioural and
neuropathologic changes in recently developed MSUD mouse
models in order to provide mechanistic insight and test ther-
apeutic interventions for MSUD encephalopathy. Examinations of
iMSUD mice showed a mouse model that develops neuropa-
thology similar to human MSUD (Crome et al., 1961; Silberman
et al., 1961), large accumulation of branched-chain amino acids,
depletion of other essential large neutral amino acids, and brain
specific growth restriction. Both iMSUD and cMSUD mice showed
neurotransmitter depletion including dopamine and glutamate, as
well as a correlation between the level of depletion with the rise
in brain leucine. Placing the iMSUD mice on a high protein diet
showed that initiation of behavioural symptoms was concomitant
with neurotransmitter depletion and more severe symptoms were
associated with energy depletion secondary to Krebs cycle disrup-
tion. The use of norleucine revealed a potential acute-treatment
for MSUD that effectively delayed encephalopathy in cMSUD
pups and iMSUD mice challenged with a high protein.
Current findings indicate a model of brain injury in MSUD that
involves two converging mechanisms: (i) amino acid competition
at the blood–brain barrier secondary to branched-chain amino acid
accumulation; and (ii) disruption of energy metabolism secondary
to branched-chain ketoacid accumulation (Fig. 10). On the one
hand, accumulation of branched-chain amino acids, especially leu-
cine, likely inhibits transport of other essential large neutral amino
acids (threonine, tryptophan and tyrosine) that share the same
transporter for brain access. This competition results in the
observed depletion of essential large neutral amino acids in
the brain with subsequent consequences for both protein and
neurotransmitter synthesis similar to previous studies of dietary
amino acid manipulation in rats (McKean et al., 1968; Tews
et al., 1991; Le Masurier et al., 2006). Impaired protein synthesis
secondary to unbalanced essential amino acids results in brain
specific growth restriction in iMSUD mice and disruption of
dendritic development in cMSUD pups. Additionally, inhibition of
neurotransmitter synthesis (dopamine) is associated with early
behavioural symptoms such as intermittent dystonia and gait
abnormalities within 48 h of protein diet exposure.
The proposed second converging mechanism in MSUD enceph-
alopathy involves energy deprivation secondary to branched-chain
ketoacid (KIC) accumulation. Severe brain damage and death in
both cMSUD and iMSUD mice correlated with accumulation of
KIC levels above 100 mmol in the brain. Similarly, enhanced sur-
vival of infant cMSUD and adult iMSUD mice with norleucine
treatment was associated with reduced levels (5100 mmol) of
KIC. Energy deprivation likely results when KIC accumulation
inhibits Krebs cycle activity as previously demonstrated in vitro
(Patel et al., 1973; Patel, 1974; Sgaravatti et al., 2003). KIC
toxicity is likely responsible for cerebral oedema as ATP depletion
leads to Na+/K+ ATPase failure and cell swelling. Increased KG
and KIC levels found in the brain of iMSUD mice on the high
protein diet are consistent with -ketoglutarate dehyrdrogenase
inhibition secondary to KIC accumulation as previously shown
(Patel, 1974). Additionally, decreases in glutamate and aspartate
are consistent with disruption of glutamate cycling secondary
to KIC accumulation as previously postulated (Yudkoff et al.,
2005). These changes are consistent with increased lactate levels
and depletion of pyruvate and ATP as shown in Fig. 10. These
data underscore the importance of branched-chain ketoacid
control and also suggests that branched-chain ketoacids are pro-
duced in the brain from available branched-chain amino acids
rather than transported in secondary to accumulation in the liver.
Similar biochemical changes were found between iMSUD and
cMSUD mice. However, these changes evolved more rapidly over
the first few days of life in cMSUD mice, which highlights the
delicate nature of MSUD in the newborn requiring prompt treat-
ment. Leucine levels were shown to accumulate exponentially,
doubling each day, in the blood and brain of newborn cMSUD
mice. These findings suggest enhanced utilization of leucine
in the normal immature brain, consistent with previous studies
that showed increased transport of branched-chain amino acids
across the blood–brain barrier in suckling versus adult rats
(Banos et al., 1978). The immature brain readily uses alternate
energy substrates such as ketone bodies (Cremer, 1982), which
may be supplied as ketogenic amino acids (i.e. leucine and lysine).
Additionally, ketogenic amino acids have been shown to provide
a substantial proportion of ketone bodies used for myelin synthe-
sis (Dhopeshwarkar and Subramanian, 1979). The pathway for
ketone body production from leucine is blocked in MSUD and
may account, in part, for disrupted myelination (Crome et al.,
1961; Silberman et al., 1961). Accordingly, we observed an
increase in brain lysine levels, which may represent compensa-
tion for ketogenic substrates similar to previously observed accu-
mulation of brain leucine when lysine breakdown is disrupted
(Zinnanti et al., 2006).
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Neuropathological changes identified in iMSUD mice are con-
sistent with previous reports of MSUD patients with inadequate
dietary control or repeated catabolic crises (Morton et al., 2002;
Simon et al., 2007). Similar to human MSUD, the iMSUD mice
were responsive to a low branched-chain amino acid diet. Neuro-
chemical analysis of these mice are consistent with MR spectros-
copy findings in human MSUD that suggested dietary intervention
could reduce brain branched-chain amino acid accumulation to
near normal levels (Jan et al., 2003). However, adult iMSUD
mice maintained on the low branched-chain amino acid diet
continue to have increased T2 signals on MRI, which is similar
to previous reports in adolescents and adults with MSUD and
suggests lingering myelin disruption (Schonberger et al., 2004).
Further study of this model may provide insight into the cause
of these residual changes and suggest ways to prevent them.
Challenging the iMSUD mice with a high protein diet induced a
catabolic crisis, which allowed the correlation of early neurochem-
ical changes with appearance of symptoms. Using this strategy,
we showed that whole brain dopamine, glutamate and GABA
depletion are concomitant with onset of initial behaviour deficits.
These findings correlate with neuropathological and behavioural
changes during encephalopathy in human MSUD, that indicate
susceptibility of motor control centers (Crome et al., 1961;
Silberman et al., 1961; Hauber, 1998; Morton et al., 2002).
Furthermore, this model shows the first direct experimental evi-
dence that dopamine levels are depleted in the brain during
MSUD encephalopathy, which has been previously suggested
based on clinical observations and reduced blood tyrosine levels
in human MSUD (Morton et al., 2002). This finding also suggests
that other catecholamines and serotonin are likely compromised
Figure 10 Proposed model of brain injury and treatment effect in MSUD. (1) Loss of branched-chain ketoacid dehydrogenase
function results in accumulation of branched-chain amino acids (mostly leucine) in blood and tissues including muscle, liver and brain.
Rapid accumulation of leucine competes with other essential large neutral amino acids using the same transporter (LAT1) for brain
access. Reduced levels of these essential amino acids inhibit protein synthesis and deplete dopamine and serotonin by limiting available
precursors. Furthermore, loss of branched-chian ketoacid dehydrogenase impairs use of leucine for myelin synthesis, combined with
impaired protein synthesis leads to dysmyelination. (2) Accumulation of branched-chain ketoacid (KIC) within astrocytes and neurons
may drive reverse transamination toward leucine resulting in increased KG/glutamate ratios. (3) An increase in KG/glutamate ratios
may inhibit the malate/aspartate shuttle resulting in increased NADH/NAD+ ratios preventing conversion of lactate to pyruvate.
Alternatively, at the mitochondrial level, accumulation of KIC has been previously shown to inhibit oxidative metabolism through
inhibition of pyruvate dehydrogenase (PDH) and -ketogutarate dehydrogenase (KGDH) resulting in Krebs cycle dysfunction.
Energy failure results in loss of Na+/ATPase function (2) leading to cell swelling and cerebral oedema. Norleucine attenuates
leucine transport across the blood–brain barrier (1) and may also limit transamination to KIC at the astrocyte level (2) and
mitochondrial leucine transport (3).
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secondary to tyrosine and tryptophan depletion. Therefore, tyro-
sine and tryptophan supplementation is expected to benefit long-
term outcomes in MSUD patients and possibly lessen or prevent
learning disabilities.
In the current study, whole brain homogenates were used for
biochemical analysis to correlate and compare changes in the
cellular amino acid pool directly with effects on Krebs cycle
function and neurotransmitter synthesis. Although, associations
can be made from these studies about whole brain metabolism,
these findings also provide targets for future studies in CSF, which
can then be compared with human MSUD for possible transla-
tional value.
Despite careful management of MSUD patients, non-specific
illness can trigger catabolic crisis leading to life threatening cere-
bral oedema, which can be extremely difficult to manage clinically
(Morton et al., 2002). Norleucine may provide an acute strategy
to control KIC levels and prevent cerebral oedema during cata-
bolic crisis. In the current study, norleucine attenuated brain leu-
cine accumulation, but had a proportionally greater affect to
control KIC levels. These data suggest that norleucine may inhibit
branched-chain transaminase in addition to competing with leu-
cine for brain access. In astrocytes, branched-chain transaminase
functions in the glutamate cycle by transferring amines from
branched-chain amino acids to KG to produce glutamate and
the associated branched-chain ketoacid (Yudkoff et al., 2005)
(Fig. 10). The opposite reaction takes place in neurons to com-
plete the glutamate cycle. In the case of MSUD, KIC accumula-
tion in neurons may drive formation of leucine and KG over
glutamate. A high KG/glutamate ratio can disrupt mitochondrial
glutamate, aspartate, malate and KG transport resulting in Krebs
cycle failure and impaired glutamate cycling (Yudkoff et al.,
2005). This hypothesis is consistent with our current findings
including increased KG, decreased glutamate and aspartate
with lactate accumulation and ATP depletion with KIC above
100mM. Additionally, control of KIC levels with norleucine treat-
ment prevented these changes and strongly supports the hypoth-
esis that KIC disrupts Krebs cycle function and glutamate cycling
(Yudkoff et al., 2005).
The current findings provide insight into the mechanism of brain
injury and potential treatment strategy for MSUD. Both iMSUD
and cMSUD mouse models were shown to be invaluable for the
study of MSUD and may also be used to study cerebral glutamate
and dopamine metabolism. Further studies in these mouse models
can help define the role of tyrosine and tryptophan supplementa-
tion in MSUD. Use of atypical amino acids to limit toxic accumu-
lation may provide effective treatments for other neurometabolic
disorders.
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